Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: OCL022
MIFTS: 41

Ocular Melanoma

Categories: Rare diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Ocular Melanoma

About this section

MalaCards integrated aliases for Ocular Melanoma:

Name: Ocular Melanoma 53 55
Malignant Melanoma of Eye 73

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Skin diseases
See all MalaCards categories (disease lists)


External Ids:

UMLS 73 C0558356
Sources

Summaries for Ocular Melanoma

About this section
NIH Rare Diseases : 53 Ocular melanoma (OM) is a cancer in pigment-producing cells of the eye called melanocytes.   Melanocytes are cells that produce the pigment melanin that colors the skin, hair, and eyes, as well as forms moles.  There are four tissues in the eye in which melanoma can develop: the uveal tract (uvea); conjunctiva; eyelid; and orbit.  The uvea - the middle layer within the eye  - is divided into three main parts: the iris, ciliary body, and choroid.  Uveal melanoma, also called intraocular melanoma, is the most common ocular melanoma. Conjunctival melanoma manifests on the surface of the eye and has been increasing in incidence. Eyelid and primary orbital melanoma are the least common variants.

MalaCards based summary : Ocular Melanoma, also known as malignant melanoma of eye, is related to bap1 tumor predisposition syndrome and skin melanoma. An important gene associated with Ocular Melanoma is MC1R (Melanocortin 1 Receptor), and among its related pathways/superpathways are Pathways in cancer and NF-kappaB Signaling. The drugs Dacarbazine and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include eye, liver and skin, and related phenotypes are hematopoietic system and endocrine/exocrine gland

Sources

Related Diseases for Ocular Melanoma

About this section

Diseases related to Ocular Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 47)
# Related Disease Score Top Affiliating Genes
1 bap1 tumor predisposition syndrome 32.2 BAP1 BRCA2
2 skin melanoma 28.7 BAP1 KIT MC1R
3 melanoma 10.8
4 peritoneum cancer 10.3 BAP1 BRCA2
5 tumor predisposition syndrome 10.3 BAP1 BRCA2
6 hepatitis 10.3
7 choroiditis 10.2
8 maxillary sinus adenoid cystic carcinoma 10.0 IL2 KIT
9 dysgerminoma of ovary 10.0 BRCA2 KIT
10 melanoma metastasis 9.9
11 melanoma, uveal 9.9
12 mast cell neoplasm 9.9 IL2 KIT
13 toxic shock syndrome 9.9 CIITA IL2
14 ocular cancer 9.8 BAP1 BRCA2 IL2
15 leukocyte disease 9.8 IL2 KIT
16 combined immunodeficiency, x-linked 9.8 CIITA IL2
17 lymphoma 9.7
18 cataract 9.7
19 melanoma, cutaneous malignant 1 9.7 BAP1 MC1R
20 leukemia 9.6
21 thyroiditis 9.6
22 mediastinitis 9.6
23 sinusitis 9.6
24 peritonitis 9.6
25 dysplastic nevus syndrome 9.6
26 type i 9.6
27 dry eye syndrome 9.6
28 syncope 9.6
29 arachnoiditis 9.6
30 malignant peritoneal mesothelioma 9.6
31 panophthalmitis 9.6
32 endotheliitis 9.6
33 retinal detachment 9.6
34 peritoneal mesothelioma 9.6
35 aging 9.6
36 budd-chiari syndrome 9.6
37 cervicitis 9.6
38 acute leukemia 9.6
39 liposarcoma 9.6
40 b-cell lymphomas 9.6
41 retinitis 9.6
42 craniopharyngioma 9.6
43 amelanotic melanoma 9.6
44 thymoma 9.5 IL2 KIT
45 integumentary system cancer 9.4 KIT MC1R
46 immune deficiency disease 9.4 CIITA IL2
47 cell type cancer 9.0 IL2 KIT MC1R

Graphical network of the top 20 diseases related to Ocular Melanoma:



Diseases related to Ocular Melanoma
Sources

Symptoms & Phenotypes for Ocular Melanoma

About this section

MGI Mouse Phenotypes related to Ocular Melanoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.91 BRCA2 SERPINF1 CIITA IL2 KIT BAP1
2 endocrine/exocrine gland MP:0005379 9.88 SERPINF1 BRCA2 CIITA IL2 KIT BAP1
3 immune system MP:0005387 9.87 BRCA2 SERPINF1 CIITA IL2 KIT BAP1
4 digestive/alimentary MP:0005381 9.83 SERPINF1 BRCA2 IL2 KIT BAP1
5 neoplasm MP:0002006 9.65 MC1R BRCA2 IL2 KIT BAP1
6 no phenotypic analysis MP:0003012 9.46 MC1R BAP1 IL2 KIT
7 pigmentation MP:0001186 9.13 MC1R SERPINF1 KIT
8 reproductive system MP:0005389 9.02 BAP1 SERPINF1 BRCA2 IL2 KIT
Sources

Drugs & Therapeutics for Ocular Melanoma

About this section

Drugs for Ocular Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 94)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dacarbazine Approved, Investigational Phase 3,Phase 2 4342-03-4 5351166
2
Bevacizumab Approved, Investigational Phase 3,Phase 2 216974-75-3
3
Melphalan Approved Phase 3,Phase 2 148-82-3 4053 460612
4
Pembrolizumab Approved Phase 3,Phase 2,Phase 1 1374853-91-4
5
Imidazole Experimental, Investigational Phase 3,Phase 2 288-32-4 795
6
Fotemustine Experimental, Investigational Phase 3
7 Alkylating Agents Phase 3,Phase 2,Phase 1
8 Angiogenesis Inhibitors Phase 3,Phase 2
9 Angiogenesis Modulating Agents Phase 3,Phase 2
10 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
11 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
12 Vaccines Phase 3,Phase 2
13 Antibodies Phase 3,Phase 2,Phase 1
14 Immunoglobulins Phase 3,Phase 2,Phase 1
15 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
16 Liver Extracts Phase 3,Phase 2,Phase 1
17 Mitogens Phase 3
18 Endothelial Growth Factors Phase 3
19
Gemcitabine Approved Phase 2 95058-81-4 60750
20
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
21
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
22
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
23
Tamoxifen Approved Phase 2 10540-29-1 2733526
24
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
25
Sorafenib Approved, Investigational Phase 2,Phase 1 284461-73-0 216239 406563
26
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
27
Lenalidomide Approved Phase 2 191732-72-6 216326
28
Mesna Approved, Investigational Phase 2 3375-50-6 598
29
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
30
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
31
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
32
Xylometazoline Approved, Investigational Phase 2 526-36-3 5709
33
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
34
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
35
Nicotinamide Approved, Investigational, Nutraceutical Phase 2,Phase 1 98-92-0 936
36
Niacin Approved, Investigational, Nutraceutical Phase 2,Phase 1 59-67-6 938
37
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 59-30-3 6037
38
Treosulfan Investigational Phase 2 299-75-2 9296
39
Entinostat Investigational Phase 2 209783-80-2
40 Selective Estrogen Receptor Modulators Phase 2
41 Hormone Antagonists Phase 2
42 Hormones Phase 2
43 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
44 Estrogen Antagonists Phase 2
45 Estrogen Receptor Modulators Phase 2
46 Estrogens Phase 2
47 Anti-Infective Agents Phase 2,Not Applicable
48 Antimetabolites Phase 2
49 Antiviral Agents Phase 2,Not Applicable
50 Bone Density Conservation Agents Phase 2

Interventional clinical trials:

(show all 47)
# Name Status NCT ID Phase Drugs
1 Collaborative Ocular Melanoma Study (COMS) Unknown status NCT00000124 Phase 3
2 Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma Recruiting NCT02678572 Phase 3 Dacarbazine;Ipilimumab;Pembrolizumab
3 Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated With Proton Therapy for a Large Choroidal Melanoma Not yet recruiting NCT03172299 Phase 3 Aflibercept Injection;False injection
4 Vaccine Therapy in Treating Patients With Melanoma of the Eye Terminated NCT00036816 Phase 3
5 Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma Terminated NCT00110123 Phase 3 fotemustine;isolated perfusion
6 Study of Metastatic Ocular Melanoma Unknown status NCT00168870 Phase 2 Gemcitabine;Treosulfan
7 Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma Unknown status NCT00489944 Phase 2 cisplatin;sunitinib malate;tamoxifen citrate
8 Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye Unknown status NCT01217398 Phase 2 temozolomide
9 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma Completed NCT01814046 Phase 2 Aldesleukin;Cyclophosphamide;Fludarabine
10 STA-9090(Ganetespib) in Metastatic Ocular Melanoma Completed NCT01200238 Phase 2 STA-9090
11 Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma Completed NCT00109005 Phase 2 Revlimid
12 THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease Completed NCT01355120 Phase 2 Ipilimumab
13 A Phase II Study of Isolated Hepatic Perfusion (IHP) in Patients With Ocular Melanoma Completed NCT00062933 Phase 2
14 Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery Completed NCT01835145 Phase 2 Cabozantinib S-malate;Dacarbazine;Temozolomide
15 Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye Completed NCT00020475 Phase 2 gp100 antigen;interleukin-2;MART-1 antigen;Montanide ISA-51
16 Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma Completed NCT00003802 Phase 2 pyrazoloacridine
17 Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma Completed NCT00085306 Phase 2
18 Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye Completed NCT01143402 Phase 2 Dacarbazine;Selumetinib;Temozolomide
19 Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye Completed NCT01413191 Phase 2
20 Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye Completed NCT00329641 Phase 2 carboplatin;paclitaxel;sorafenib tosylate
21 Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery Completed NCT00738361 Phase 2 nab-paclitaxel
22 Taxoprexin® Treatment for Advanced Eye Melanoma Completed NCT00244816 Phase 2 Taxoprexin
23 Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye Recruiting NCT02697630 Phase 2 Pembrolizumab;Entinostat
24 Study in Subjects With Small to Medium Primary Choroidal Melanoma Recruiting NCT03052127 Phase 1, Phase 2 Light-activated AU-011
25 Study With T-cel Receptor Gene Therapy in Metastatic Melanoma Recruiting NCT02654821 Phase 1, Phase 2
26 Vorinostat in Treating Patients With Metastatic Melanoma of the Eye Active, not recruiting NCT01587352 Phase 2 Vorinostat
27 Study Assessing Two Models of Hypofractionated Protontherapy on Large Choroidal Melanomas Active, not recruiting NCT02602756 Phase 2
28 SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver Active, not recruiting NCT01473004 Phase 2
29 Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma Not yet recruiting NCT03528408 Phase 2 Nivolumab;Ipilimumab
30 CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301 in Treating Patients With Stage IIB-IV Melanoma Suspended NCT02129075 Phase 2
31 Imatinib in Adult Patients With Metastatic Ocular Melanoma Terminated NCT00421317 Phase 2 Imatinib
32 Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma Terminated NCT00482911 Phase 2 cyclophosphamide;lenalidomide;sunitinib malate
33 A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma Terminated NCT01801358 Phase 1, Phase 2 AEB071;MEK162
34 Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma Completed NCT01893099 Phase 1 Sorafenib
35 Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate Completed NCT01046487 Phase 1 Imatinib mesylate, Cyclophosphamide (Dosing level 1 );Imatinib mesylate, Cyclophosphamide (Dosing level 2);Imatinib mesylate, Cyclophosphamide (Dosing level 3)
36 Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 Recruiting NCT02315066 Phase 1 PF-04518600;PF-04518600;PF-04518600 plus PF-05082566;PF-04518600 plus PF-05082566
37 Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases Recruiting NCT02858869 Phase 1
38 Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone Completed NCT00351728
39 Study of Tumor Samples in Patients Undergoing Radiation Therapy or Surgery For Primary Melanoma of the Eye Completed NCT00952939
40 Cytogenetic Study of Ocular Melanoma Recruiting NCT00344799
41 Optical Coherence Tomography of Retinal Abnormalities Associated With Choroidal Nevus, Choroidal Melanoma and Choroidal Melanoma Treated With Iodine-125 Brachytherapy Recruiting NCT00346372
42 The Role of Inflammation in Ocular Tumours Recruiting NCT02909517
43 5 Year Registry Study to Track Clinical Application of DecisionDx-UM Assay Results and Associated Patient Outcomes Active, not recruiting NCT02376920
44 Definity for Ultrasound of Intraocular Tumors Not yet recruiting NCT01930968
45 Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver No longer available NCT01728051 Melphalan
46 Investigative Trial of Interferon Alpha-2b To Shrink Cancer of the Eye Withdrawn NCT00621439 Not Applicable Pegylated Interfon Alpha 2B;Placebo
47 Validation of a Molecular Prognostic Test for Eye Melanoma Withdrawn NCT00406120

Search NIH Clinical Center for Ocular Melanoma

Sources

Genetic Tests for Ocular Melanoma

About this section
Sources

Anatomical Context for Ocular Melanoma

About this section

MalaCards organs/tissues related to Ocular Melanoma:

41
Eye, Liver, Skin, Testes, Endothelial, Bone, Lung
Sources

Publications for Ocular Melanoma

About this section

Articles related to Ocular Melanoma:

(show top 50) (show all 337)
# Title Authors Year
1
Hepatic artery infusion of melphalan in patients with liver metastases from ocular melanoma. ( 29878390 )
2018
2
Gamma irradiation of ocular melanoma and lymphoma cells in the presence of gold nanoparticles: inA vitro study. ( 29707895 )
2018
3
Outcomes of cataract surgery in eyes with ocular melanoma treated with iodine-125 brachytherapy. ( 29703285 )
2018
4
Ocular melanoma-when you have seen one, you have not seen them all: a clinical outcome study from the Surveillance, Epidemiology and End Results (SEER) database (1973-2012). ( 28115829 )
2017
5
Health-related quality of life during trans-arterial chemoembolization with drug-eluting beads loaded with doxorubicin (DEBDOX) for unresectable hepatic metastases from ocular melanoma. ( 28754534 )
2017
6
Comment on "Milham & Stetzer (2016) Tumor-specific frequencies and ocular melanoma." Electromag Biol Med http://dx.doi.org/10.1080/15368378.2016.1234390. ( 27715332 )
2017
7
PRL-3/PTP4A3 phosphatase regulates integrin I^1 in adhesion structures during migration of human ocular melanoma cells. ( 28284838 )
2017
8
Dry Eye Syndrome After Proton Therapy of Ocular Melanomas. ( 28586953 )
2017
9
Reproducibility of a Noninvasive System for Eye Positioning and Monitoring in Stereotactic Radiotherapy of Ocular Melanoma. ( 28168935 )
2017
10
Dynamic Contrast-Enhanced Magnetic Resonance Imaging of Ocular Melanoma as a Tool to Predict Metastatic Potential. ( 28448404 )
2017
11
The toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism. ( 26655090 )
2016
12
EPIDEMIOLOGICAL ANALYSIS OF OCULAR MELANOMA IN UNIVERSITY CLINIC CENTER IN TUZLA, BOSNIA AND HERZEGOVINA. ( 27698609 )
2016
13
Imaging of ocular melanoma metastasis. ( 27168029 )
2016
14
A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib. ( 27520988 )
2016
15
Feasibility of Proton Beam Therapy for Ocular Melanoma Using a Novel 3D Treatment Planning Technique. ( 27084652 )
2016
16
Tumor-specific frequencies and ocular melanoma. ( 27552371 )
2016
17
Metastatic melanoma after 23a88years of primary ocular melanoma. ( 27881589 )
2016
18
Head and neck melanoma (excluding ocular melanoma): United Kingdom National Multidisciplinary Guidelines. ( 27841141 )
2016
19
Overexpression of hepatocyte growth factor and an oncogenic CDK4 variant in mice alters corneal stroma morphology but does not lead to spontaneous ocular melanoma. ( 26731561 )
2016
20
Investigating the dosimetric impact of seed location uncertainties in Collaborative Ocular Melanoma Study-based eye plaques. ( 27475484 )
2016
21
Metastatic Ocular Melanoma to the Liver Exhibits Infiltrative and Nodular Growth Patterns. ( 27476775 )
2016
22
Diffusion-weighted magnetic resonance imaging for predicting and detecting the response of ocular melanoma to proton beam therapy: initial results. ( 25578783 )
2015
23
Dynamic contrast-enhanced MRI of ocular melanoma. ( 25714038 )
2015
24
Nationwide Incidence of Ocular Melanoma in South Korea by Using the National Cancer Registry Database (1999-2011). ( 26207308 )
2015
25
Heterogeneous dose calculations for Collaborative Ocular Melanoma Study eye plaques using actual seed configurations and Task Group Report 43 formalism. ( 25533415 )
2015
26
A challenging case of ocular melanoma. ( 26429178 )
2015
27
Low thyroid hormone levels improve survival in murine model for ocular melanoma. ( 25868390 )
2015
28
Metastatic Ocular Melanoma Presenting as a Heart-Compressing Mediastinal Mass. ( 26434443 )
2015
29
Evidence-based integration of selective internal radiation therapy into the management of ocular melanoma liver metastases. ( 25478778 )
2014
30
Method for verifying the air kerma strength of I-125 plaques for the treatment of ocular melanoma. ( 25207419 )
2014
31
Effects of defining realistic compositions of the ocular melanoma on proton therapy. ( 25599060 )
2014
32
Ocular melanoma and the BAP1 hereditary cancer syndrome: implications for the dermatologist. ( 24697775 )
2014
33
Isolated Hepatic Perfusion for Ocular Melanoma Metastasis: Registry Data Suggests a Survival Benefit. ( 24141377 )
2013
34
Combined surgical resection and radiofrequency ablation as treatment for metastatic ocular melanoma. ( 22766897 )
2013
35
Pretherapeutic laboratory findings, extent of metastasis and choice of treatment as prognostic markers in ocular melanoma- a single centre experience. ( 23057648 )
2013
36
Progression of ocular melanoma metastasis to the liver: the 2012 Zimmerman lecture. ( 23392528 )
2013
37
Ocular melanoma: an overview of the current status. ( 23826405 )
2013
38
Ocular melanoma metastasizing to intra-abdominal lymph nodes. ( 23762736 )
2013
39
The Collaborative Ocular Melanoma Study, mortality by therapeutic approach, age and tumor size. ( 24069782 )
2013
40
Solitary secondary malignant melanoma of clavicle two years after enuclation for ocular melanoma. ( 23424696 )
2013
41
Diffusion-weighted imaging of ocular melanoma. ( 23614974 )
2013
42
Left ventricular metastasis from ocular melanoma: a new, rare, and unusual pathway? ( 23816109 )
2013
43
TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. ( 23799844 )
2013
44
SECONDARY NEUTRON DOSES IN PROTON THERAPY TREATMENTS OF OCULAR MELANOMA AND CRANIOPHARYNGIOMA. ( 24222710 )
2013
45
Baker's Cyst on F-18 FDG PET/CT in a Patient with Ocular Melanoma. ( 23486655 )
2012
46
Ocular immune privilege and ocular melanoma: parallel universes or immunological plagiarism? ( 22707951 )
2012
47
Ocular melanoma metastasis to the cervical spine. ( 22245271 )
2012
48
Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-I_B pathways. ( 22653968 )
2012
49
Ocular melanoma in a patient successfully treated for diffuse malignant peritoneal mesothelioma: a case report. ( 22613358 )
2012
50
Ocular melanoma. ( 23960984 )
2012
Sources

Variations for Ocular Melanoma

About this section
Sources

Expression for Ocular Melanoma

About this section
Search GEO for disease gene expression data for Ocular Melanoma.
Sources

Pathways for Ocular Melanoma

About this section

Pathways related to Ocular Melanoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Pathways in cancer 37
12.22 BRCA2 IL2 KIT
2
NF-kappaB Signaling 4
11.65 CIITA IL2 KIT
3
Innate Lymphoid Cell Differentiation Pathways 65
11.16 IL2 KIT
4
Dendritic Cells Developmental Lineage Pathway 65
11.02 IL2 KIT
5
Melanocyte Development and Pigmentation 64
10.24 KIT MC1R
Sources

GO Terms for Ocular Melanoma

About this section

Biological processes related to Ocular Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intracellular signal transduction GO:0035556 9.5 CIITA KIT MC1R
2 hemopoiesis GO:0030097 9.26 BRCA2 KIT
3 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.16 IL2 KIT
4 pigmentation GO:0043473 8.96 KIT MC1R
5 T cell differentiation GO:0030217 8.62 IL2 KIT
Sources

Sources for Ocular Melanoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....